ZURA net incomeQ3 2026-$25.82M
ZURA net income was -$25.82M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$18.04M a year earlier. For the full fiscal 2025 it was -$68.65M, compared with -$52.40M in fiscal 2024.
Zura Bio Limited (ZURA) financials
For the twelve months ended Sep 30, 2026, Zura Bio Limited reported -$93.53M of net income.
- Net income, TTM
- -$93.53M
- Free cash flow, TTM
- -$64.97M
- EPS, diluted, TTM
- -$1.12
- Cash
- $187.65M
- Market cap
- $135.8M
FY2022FY2025
FY2024FY2025
ZURA revenue and earnings growth
ZURA EPSQ3 2026-$0.20
ZURA diluted EPS was -$0.20 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.21 a year earlier. For the full fiscal 2025 it was -$1.06, compared with -$0.60 in fiscal 2024.
ZURA free cash flowQ3 2026-$19.5K
ZURA free cash flow was -$19.5K in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$15.5K a year earlier. For the full fiscal 2025 it was -$64.93M, compared with -$28.15M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Research and development | $42.08M | $24.40M | $44.00M | - |
| Selling, general and admin | $33.16M | $30.79M | $18.64M | $2.29M |
| Operating income | -$75.25M | -$55.19M | -$62.64M | -$2.68M |
| Pre-tax income | -$68.65M | -$52.40M | -$60.56M | - |
| Income tax | - | $0 | $0 | - |
| Net income | -$68.65M | -$52.40M | -$60.36M | -$25.70M |
| EPS, basic | -$1.06 | -$0.60 | -$2.09 | - |
| EPS, diluted | -$1.06 | -$0.60 | -$2.09 | - |
| Diluted shares | 94.2M | 75.1M | 33.1M | - |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $109.41M | $176.5K | $99.81M | $1.57M |
| Current assets | $112.31M | $178.74M | $100.84M | $1.78M |
| Total assets | $113.95M | $179.53M | $100.84M | $5.26M |
| Current liabilities | $12.41M | $19.51M | $20.30M | $14.82M |
| Total liabilities | $12.41M | $19.51M | $21.29M | $14.82M |
| Shareholders' equity | $101.54M | $148.36M | $60.87M | -$32.06M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$64.81M | -$28.08M | -$15.05M | -$1.07M |
| Capital expenditures | $113.0K | $75.0K | - | - |
| Free cash flow | -$64.93M | -$28.15M | - | - |
| Investing cash flow | -$113.0K | -$5.08M | -$8.00M | - |
| Financing cash flow | -$2.16M | $109.84M | $121.29M | $355.6K |
| Stock-based compensation | $12.33M | $16.80M | $7.47M | - |
| Depreciation and amortization | $49.0K | $9.0K | - | - |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $19.49M | $20.71M | $14.75M | $10.96M | $11.95M | $8.70M | $10.47M | $9.24M | $6.03M | $5.54M | $3.59M | $6.92M |
| Selling, general and admin | $9.28M | $8.62M | $10.75M | $7.46M | $7.57M | $9.36M | $8.78M | $6.49M | $13.29M | $6.22M | $4.79M | $3.91M |
| Operating income | -$28.77M | -$29.32M | -$25.50M | -$18.41M | -$19.52M | -$18.06M | -$19.25M | -$15.73M | -$19.32M | -$11.76M | -$8.38M | -$10.83M |
| Pre-tax income | -$27.05M | -$26.39M | -$24.22M | -$17.18M | -$18.04M | -$15.99M | -$17.44M | -$13.63M | -$20.70M | -$10.33M | -$7.75M | -$8.47M |
| Income tax | -$1.22M | -$81.0K | $0 | - | $0 | $0 | $0 | - | - | - | - | - |
| Net income | -$25.82M | -$26.30M | -$24.22M | -$17.18M | -$18.04M | -$15.99M | -$17.44M | -$13.63M | -$20.70M | -$10.33M | -$7.75M | -$8.47M |
| EPS, basic | -$0.20 | -$0.21 | -$0.22 | -$0.49 | -$0.21 | -$0.17 | -$0.19 | - | -$0.26 | -$0.17 | -$0.02 | - |
| EPS, diluted | -$0.20 | -$0.21 | -$0.22 | -$0.49 | -$0.21 | -$0.17 | -$0.19 | - | -$0.26 | -$0.17 | -$0.02 | - |
| Diluted shares | 127.7M | 126.8M | 112.2M | - | 94.6M | 94.3M | 93.0M | - | 87.3M | 74.9M | 46.9M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $187.65M | $205.13M | $225.59M | $109.41M | $139.0K | $154.5K | $170.57M | $176.5K | $188.22M | $188.44M | $89.82M | $99.81M |
| Current assets | $191.59M | $210.50M | $227.00M | $112.31M | $142.29M | $156.99M | $171.69M | $178.74M | $188.97M | $189.47M | $90.47M | $100.84M |
| Total assets | $194.63M | $213.40M | $228.64M | $113.95M | $143.94M | $157.81M | $172.50M | $179.53M | $189.07M | $189.50M | $90.48M | $100.84M |
| Current liabilities | $16.97M | $16.32M | $11.74M | $12.41M | $25.49M | $18.70M | $21.09M | $19.51M | $18.24M | $15.07M | $14.67M | $20.30M |
| Total liabilities | $16.97M | $16.32M | $11.74M | $12.41M | $25.49M | $18.70M | $21.09M | $19.51M | $18.24M | $17.44M | $16.27M | $21.29M |
| Shareholders' equity | $177.66M | $197.09M | $216.90M | $101.54M | $109.78M | $127.45M | $139.74M | $148.36M | $154.29M | $158.06M | $62.55M | $60.87M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.5K | $18.88M | -$18.92M | -$64.77M | -$15.4K | $11.04M | -$11.06M | -$10.82M | -$5.65M | -$6.62M | -$4.98M | -$4.05M |
| Capital expenditures | $36 | -$13.0K | $13.0K | $112.9K | $32 | -$48.9K | $49.0K | $45.0K | $13.0K | $10.0K | $7.0K | - |
| Free cash flow | -$19.5K | $18.87M | -$18.94M | -$64.89M | -$15.5K | $10.99M | -$11.11M | -$10.87M | -$5.67M | -$6.63M | -$4.99M | - |
| Investing cash flow | -$36 | $13.0K | -$13.0K | -$112.9K | -$32 | $48.9K | -$49.0K | -$45.0K | -$13.0K | -$10.0K | -$5.01M | $0 |
| Financing cash flow | $2.1K | -$134.99M | $135.12M | -$2.17M | $3 | -$5.18M | $5.18M | -$854.0K | $5.44M | - | - | $0 |
| Stock-based compensation | $5.3K | -$5.00M | $5.01M | $12.32M | $2.4K | -$3.64M | $3.64M | $2.82M | $8.65M | $2.93M | $2.41M | $2.39M |
| Depreciation and amortization | $20 | -$16.0K | $16.0K | $49.0K | $14 | -$9.0K | $9.0K | $5.0K | $3.0K | - | - | - |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 11.29 | 12.90 | 19.33 | 9.05 | 5.58 | 8.40 | 8.14 | 9.16 | 10.36 | 12.57 | 6.17 | 4.97 |
Source: XBRL data Zura Bio Limited files with the SEC, latest filing dated Oct 27, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ZURA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ZURA | - | - | -$93.53M | - | $135.8M |
| ACRS | $6.40M | -59.3% | -$79.63M | -1244.1% | $658.2M |
| ARQT | $508.68M | +60.0% | $29.91M | 5.9% | $3.46B |
| KNSA | $945.96M | +58.2% | $109.57M | 11.6% | $7.47B |
| PTGX | $551.69M | +163.7% | $342.26M | 62.0% | $8.89B |
ZURA FAQ
6 questionsIs ZURA profitable?
No. Zura Bio Limited reported a net loss of $93.53M for the twelve months ended Sep 30, 2026.How much cash and debt does ZURA have?
Zura Bio Limited reported $187.65M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is ZURA free cash flow?
Zura Bio Limited generated -$64.97M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$64.83M less capital expenditures.What is ZURA earnings per share?
Diluted earnings per share were -$1.12 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did ZURA last report financial results?
The latest statements here come from Zura Bio Limited's 10-Q filed on Oct 27, 2026, covering the period ended Sep 30, 2026.Where does this ZURA financial data come from?
Quantisnow builds these statements from the structured XBRL data Zura Bio Limited files with the SEC. It is provided for information only and is not investment advice.